Abstract: The present invention includes compositions of porous-wall hollow glass microspheres and one or more biomolecules, wherein the one or more biomolecules are positioned within a void location within the hollow glass microsphere, and the use of such compositions for the diagnostic and/or therapeutic delivery of biomolecules.
Type:
Grant
Filed:
January 13, 2012
Date of Patent:
September 17, 2013
Assignees:
Georgia Health Sciences University Research Institute, Inc., Savannah River Nuclear Solutions, LLC
Inventors:
Shuyi Li, William S. Dynan, George Wicks, Steven Serkiz
Abstract: A lentivector has been engineered to express a fusion antigen composed of hepatitis B surface protein (HBsAg) and IgG2a Fc fragment (HBS-Fc-Iv) to increase both the magnitude of CD8 response and to induce effective co-activation of CD4 T cells. Immunization with this HBS-Fc-Iv caused significant regression of established tumors. Immunological analysis revealed that, compared to HBS-Iv without the Fc fragment, immunization with HBS-Fc-Iv markedly increased the number of functional CD8 and CD4 T cells and the level of Th1/Tc1-like cytokines in the tumor, while substantially decreasing the Treg ratio. The favorable immunologic changes in tumor lesions and the improvement of antitumor effects from HBS-Fc-Iv immunization were dependent on the CD4 activation, which was Fc receptor mediated. Adoptive transfer of the CD4 T cells from the HBS-Fc-Iv immunized mice could activate endogenous CD8 T cells in an IFN?-dependent manner.
Type:
Application
Filed:
March 7, 2013
Publication date:
September 12, 2013
Applicant:
Georgia Health Sciences University Research Institute, Inc.
Abstract: The present invention provides a method of treating a corneal disorder comprising administering to a patient in need thereof a composition containing pharmaceutically effective amount of dioleoylphosphatidylglycerol and/or palmitoyloleoylphosphatidylglycerol and a pharmaceutically acceptable carrier.
Type:
Grant
Filed:
April 29, 2011
Date of Patent:
September 3, 2013
Assignee:
Georgia Health Sciences University Research Institute, Inc.
Abstract: Prodrugs made up of biologically-active short-chain fatty acids or derivatives thereof conjugated to neutral or cationic amino acids capable of intracellular transport by ATB0,+ are provided. The short-chain fatty acid or derivative thereof can be attached to the amino acid through a hydroxyl group of the amino acid to form a fatty acid ester of the amino acid, or it can be attached through the amino group of the amino acid to form a fatty-acid amide of the amino acid. Serine butyrate (O-butyryl serine) is a preferred prodrug. These prodrugs are useful for treatment of colon cancer, inflammatory bowel disease, ulcerative colitis, Crohn's disease, lung cancer, cervical cancer, and cancers resulting from metastases from primary colon cancer sites. Methods of delivering biologically-active short-chain fatty acids or derivatives thereof to cells in need of these molecules and methods of treating diseases using the prodrugs of this invention are also provided.
Type:
Grant
Filed:
March 3, 2011
Date of Patent:
August 27, 2013
Assignee:
Georgia Health Sciences University Research Institute, Inc.
Inventors:
Vadivel Ganapathy, Puttur D. Prasad, Robert G. Martindale
Abstract: It has been discovered that STAT5 phosphorylation and CD150 are effective biomarkers for detecting, diagnosing, and monitoring hematological malignancies, including for example lymphomas. Compositions and methods for identifying therapeutic agents for the treatment of hematologic malignancies using p-STAT5, CD150 or both as biomarkers are described.
Type:
Application
Filed:
February 7, 2013
Publication date:
August 15, 2013
Applicant:
Georgia Health Sciences University Research Institute, Inc.
Inventor:
Georgia Health Sciences University Research Institute, Inc.
Abstract: An attachment for a wheelchair includes a secondary front-wheel pair that is movable from a disengaged up position, to a deployed down position, and back again. In the disengaged up position, the secondary front wheels are up off the ground, so the primary front wheels of the wheelchair are in contact with the ground and thereby being used. In the deployed down position, the secondary front wheels are down in contact with the ground and are thereby being used, so the primary front wheels are now removed from contact with the ground and are no longer in use. In typical embodiments, the secondary front wheels are relatively larger wheels for traversing rough terrain, the primary front wheels are relatively smaller wheels for traversing smooth terrain, and the secondary front wheels move between the disengaged up position and the deployed down position in a pivoting motion.
Type:
Application
Filed:
July 2, 2012
Publication date:
January 10, 2013
Applicant:
Georgia Health Sciences University Research Institute, Inc.
Abstract: Modified green tea polyphenols and methods of their use are provided. One aspect provides compounds and compositions containing green tea polyphenols with one on more ester-linked fatty acids.
Type:
Grant
Filed:
August 10, 2006
Date of Patent:
December 13, 2011
Assignee:
Georgia Health Science University Research Institute, Inc.